Changes in platelet, granulocyte, and complement activation during cardiopulmonary bypass using heparin-coated equipment.
The effects of heparin-coated cardiopulmonary bypass (CPB) systems on platelet, granulocyte, and complement activation were investigated during cardiopulmonary bypass. Thirty patients underwent coronary artery bypass surgery with a heparin-coated (Carmeda Bio-Active Surface, CBAS, Medtronic, U.S.A.) CPB system (HC group, n = 10), a heparin-coated oxygenator and uncoated CPB circuit (HO group, n = 10), or an uncoated system (UC group, n = 10). In the HO group, plasma C3a (1667 +/- 632 ng/ml) and C4a (1088 +/- 319 ng/ml) concentrations were significantly (p < 0.05) lower than in the UC group (2846 +/- 1045 ng/ml and 1494 +/- 480 ng/ml, respectively) 10 min after the administration of protamine, but there were no significant differences in the platelet or granulocyte counts. In the HC group, granulocyte elastase concentrations 120 min after the onset of CPB (365 +/- 177 micrograms/L) and 10 min after the administration of protamine (676 +/- 314 micrograms/L) were significantly (p < 0.05) lower than in the other 2 groups (820 +/- 341 and 893 +/- 303 micrograms/L and 1365 +/- 595 and 1,258 +/- 622 micrograms/L). In addition, the increase in the plasma C3a concentration in the HC group 60 (p < 0.05) and 120 min after the onset of CPB (p < 0.05) was significantly less than in the other 2 groups. The C3a and C4a concentrations 10 min after the administration of protamine were significantly (p < 0.005 and p < 0.05) less in the HC group than in the UC group. Platelet counts 10 min after the administration of protamine were significantly higher (p < 0.05) and plasma beta-thromboglobulin concentrations during CPB were significantly lower in the HC group than in the other 2 groups 5 (p < 0.05), 60, and 120 min (p < 0.005) after the onset of CPB. Postoperative blood loss during the first 12 h in the HC group was significantly (p < 0.05) less than that in the UC group. The heparin-coated oxygenator and uncoated CPB circuit reduced complement activation but demonstrated no significant effects on the platelet and granulocyte systems. However, the heparin-coated CPB circuit (with all components making blood contact) reduced platelet, granulocyte, and complement activation and significantly reduced postoperative blood loss. Therefore, heparin coating of CPB systems improves biocompatibility.
Fukutomi
M
M
Department of Surgery III, Nara Medical College, Japan.
Kobayashi
S
S
Niwaya
K
K
Hamada
Y
Y
Kitamura
S
S
D000328:Adult; D000368:Aged; D001672:Biocompatible Materials; D001792:Blood Platelets / Q000166:cytology / Q000187:drug effects* / Q000502:physiology; D002315:Cardiopulmonary Bypass / Q000009:adverse effects; D003167:Complement Activation / Q000187:drug effects* / Q000502:physiology; D005260:Female; D005343:Fibrinolytic Agents / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D006098:Granulocytes / Q000166:cytology / Q000187:drug effects* / Q000502:physiology; D006493:Heparin / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D007958:Leukocyte Count / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D010107:Oxygenators, Membrane / Q000592:standards; D015539:Platelet Activation / Q000187:drug effects; D010976:Platelet Count / Q000187:drug effects; D011183:Postoperative Complications / Q000517:prevention & control; D001620:beta-Thromboglobulin / Q000378:metabolism
D001672:Biocompatible Materials; D005343:Fibrinolytic Agents; D001620:beta-Thromboglobulin; D006493:Heparin